PCSK9 and myocardial ischemia: All these findings allow us to speculate that PCSK9 may represent a potentially valuable biomarker for the risk stratification of patients with STEMI and that the “PCSK9i fast track” strategy may be considered a tool, independently of starting LDL-C values, to fight myocardial ischemia–reperfusion injury [25].